{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:29:34Z","timestamp":1790688574901,"version":"4.1.0"},"reference-count":135,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009367","name":"Mansoura University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009367","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hereditas"],"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Enhancers are critical cis-regulatory elements that regulate gene expression in a context-dependent manner by integrating transcription factor binding, chromatin state, and the three-dimensional organization of the genome. Recent advances in functional genomics and synthetic biology have increased interest in harnessing enhancer activity to regulate the expression of therapeutic genes. Unlike traditional approaches that rely on promoter-driven gene regulation, enhancer-based approaches can bias transgene expression toward specific cellular states or disease contexts; however, this control remains probabilistic and highly dependent on the chromatin environment. This review summarizes current knowledge of enhancer biology, discusses new strategies for utilizing enhancer function directly, and examines the potential benefits and drawbacks of using enhancer-based strategies for gene therapy applications. Often delivered using adeno-associated virus (AAV) vectors with tailored capsids, enhancers in gene therapy can be included into expression cassettes. Astrocyte- or microglia-specific enhancers in the brain enable enriched or preferential distribution of neuroprotective or immunomodulatory genes, hence lowering unintentional expression in non-target cell types. It is important to control gene expression for specific cell types for the treatment of neurodegenerative conditions such as Alzheimer\u2019s or Parkinson\u2019s disease, were unintentional gene expression results in negative consequences. However, the uses of enhancer-guided gene therapy go beyond the central nervous system. In cancer, therapeutic constructs are designed to inhibit oncogenic expression or induce tumor suppression pathways, using enhancers in either malignant or immune cells as a target. Similarly, through the use of tissue-specific enhancers in cardiovascular and regenerative medicine, lineage-enriched genes can be used to promote repair of damaged tissues and enhance functional recovery. Enhancer-based systems that modulate the levels of gene expression (enhancer systems that adjust gene expression to levels that are physiologically appropriate for a given cell type) may also be useful in diseases caused by imbalances of gene dosage (e.g., haploinsufficiency and copy number variations). However, despite the potential promise of enhancer-driven gene therapy, many technical and translational hurdles remain. Mapping and validating the function of cell-type-specific enhancers is hampered by the dynamic, context-dependent regulation of chromatin. The identification of enhancers across a variety of developmental stages and clinical states is being accelerated through the combination of recent advances in single-cell epigenomic techniques (e.g., ATAC-seq, ChIP-seq, and multi-omic integration). Recent advances in non-viral delivery methods and AAV capsid engineering are improving the safety, efficacy, and scalability of enhancer-driven gene therapies. However, there must be careful regulatory oversight to avoid unintentional activation of enhancers and ensure continuing efficacy of enhancer-guided therapies. This paper provides an overview of the conceptual basis of enhancer-driven gene therapies, the currently available applications, and barriers to their clinical application. We show how the combination of delivery technology, synthetic biology, and genomics is enabling new possibilities for tailored gene therapy particular to cell- and disease-specific. Enhancer-driven gene therapy could become an important component of next-generation precision medicine by addressing current challenges and using creative technology.<\/jats:p>","DOI":"10.1186\/s41065-026-00655-0","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T01:25:54Z","timestamp":1774056354000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Enhancer-based gene therapy: a new path for precision medicine"],"prefix":"10.1186","volume":"163","author":[{"given":"Hany E.","family":"Marei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,21]]},"reference":[{"key":"655_CR1","doi-asserted-by":"publisher","first-page":"e3015","DOI":"10.1002\/jgm.3015","volume":"20","author":"SL Ginn","year":"2018","unstructured":"Ginn SL, Amaya AK, Alexander IE, Edelstein M, Abedi MR. Gene therapy clinical trials worldwide to 2017: an update. J Gene Med. 2018;20:e3015.","journal-title":"J Gene Med"},{"key":"655_CR2","doi-asserted-by":"publisher","first-page":"eaan4672","DOI":"10.1126\/science.aan4672","volume":"359","author":"CE Dunbar","year":"2018","unstructured":"Dunbar CE, et al. Gene therapy comes of age. Science. 2018;359:eaan4672.","journal-title":"Science"},{"key":"655_CR3","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nature15818","volume":"526","author":"L Naldini","year":"2015","unstructured":"Naldini L. Gene therapy returns to centre stage. Nature. 2015;526:351\u201360.","journal-title":"Nature"},{"key":"655_CR4","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1038\/s41588-019-0538-0","volume":"51","author":"CP Fulco","year":"2019","unstructured":"Fulco CP, et al. Activity-by-contact model of enhancer\u2013promoter regulation from thousands of CRISPR perturbations. Nat Genet. 2019;51:1664\u20139.","journal-title":"Nat Genet"},{"key":"655_CR5","doi-asserted-by":"publisher","first-page":"10843","DOI":"10.3390\/ijms241310843","volume":"24","author":"X Wang","year":"2023","unstructured":"Wang X, Liu D, Luo J, Kong D, Zhang Y. Exploring the role of Enhancer-Mediated transcriptional regulation in precision biology. Int J Mol Sci. 2023;24:10843.","journal-title":"Int J Mol Sci"},{"key":"655_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/epigenomes5040021","volume":"5","author":"SS Maurya","year":"2021","unstructured":"Maurya SS. Role of enhancers in development and diseases. Epigenomes. 2021;5:21.","journal-title":"Epigenomes"},{"key":"655_CR7","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nature14590","volume":"523","author":"JD Buenrostro","year":"2015","unstructured":"Buenrostro JD, et al. Single-cell chromatin accessibility reveals principles of regulatory variation. Nature. 2015;523:486\u201390.","journal-title":"Nature"},{"key":"655_CR8","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.3390\/cells8101281","volume":"8","author":"J-H Xia","year":"2019","unstructured":"Xia J-H, Wei G-H. Enhancer dysfunction in 3D genome and disease. Cells. 2019;8:1281.","journal-title":"Cells"},{"key":"655_CR9","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Blas CB et al. Enhancer grammar of liver cell types and hepatocyte zonation states. bioRxiv 2022\u201312. 2022.","DOI":"10.1101\/2022.12.08.519575"},{"key":"655_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/imr.13305","volume":"322","author":"HY Ghanim","year":"2024","unstructured":"Ghanim HY, Porteus MH. Gene regulation in inborn errors of immunity: implications for gene therapy design and efficacy. Immunol Rev. 2024;322:157\u201377.","journal-title":"Immunol Rev"},{"key":"655_CR11","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.1182\/blood-2023-186031","volume":"142","author":"B Zheng","year":"2023","unstructured":"Zheng B, et al. Efficacy and safety of brl-101, crispr-cas9-mediated gene editing of the bcl11a enhancer in transfusion-dependent \u03b2-thalassemia. Blood. 2023;142:4995\u20134995.","journal-title":"Blood"},{"key":"655_CR12","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41392-021-00645-w","volume":"6","author":"C Zhuo","year":"2021","unstructured":"Zhuo C, et al. Spatiotemporal control of CRISPR\/Cas9 gene editing. Signal Transduct Target Therapy. 2021;6:238.","journal-title":"Signal Transduct Target Therapy"},{"key":"655_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13148-023-01446-4","volume":"15","author":"A-J Roura","year":"2023","unstructured":"Roura A-J, et al. Regulatory networks driving expression of genes critical for glioblastoma are controlled by the transcription factor c-Jun and the pre-existing epigenetic modifications. Clin Epigenetics. 2023;15:29.","journal-title":"Clin Epigenetics"},{"key":"655_CR14","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.molmed.2021.07.012","volume":"27","author":"A Claringbould","year":"2021","unstructured":"Claringbould A, Zaugg JB. Enhancers in disease: molecular basis and emerging treatment strategies. Trends Mol Med. 2021;27:1060\u201373.","journal-title":"Trends Mol Med"},{"key":"655_CR15","doi-asserted-by":"publisher","first-page":"e3002112","DOI":"10.1371\/journal.pbio.3002112","volume":"21","author":"Q Huang","year":"2023","unstructured":"Huang Q, et al. Targeting AAV vectors to the central nervous system by engineering capsid\u2013receptor interactions that enable crossing of the blood\u2013brain barrier. PLoS Biol. 2023;21:e3002112.","journal-title":"PLoS Biol"},{"key":"655_CR16","doi-asserted-by":"publisher","first-page":"747726","DOI":"10.3389\/fnins.2021.747726","volume":"15","author":"JM Fischell","year":"2021","unstructured":"Fischell JM, Fishman PS. A multifaceted approach to optimizing AAV delivery to the brain for the treatment of neurodegenerative diseases. Front NeuroSci. 2021;15:747726.","journal-title":"Front NeuroSci"},{"key":"655_CR17","doi-asserted-by":"publisher","first-page":"e69479","DOI":"10.7554\/eLife.69479","volume":"10","author":"JT Lambert","year":"2021","unstructured":"Lambert JT, Su-Feher L, Cichewicz K, Warren TL, Zdilar I, Wang Y, et al. Parallel functional testing identifies enhancers active in early postnatal mouse brain. Elife. 2021;10:e69479.","journal-title":"Elife"},{"key":"655_CR18","doi-asserted-by":"publisher","first-page":"5404","DOI":"10.3390\/cancers14215404","volume":"14","author":"S Ito","year":"2022","unstructured":"Ito S, Das ND, Umehara T, Koseki H. Factors and mechanisms that influence chromatin-mediated enhancer\u2013promoter interactions and transcriptional regulation. Cancers. 2022;14:5404.","journal-title":"Cancers"},{"key":"655_CR19","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.3389\/fonc.2020.01387","volume":"10","author":"F Uddin","year":"2020","unstructured":"Uddin F, Rudin CM, Sen T. CRISPR gene therapy: applications, limitations, and implications for the future. Front Oncol. 2020;10:1387.","journal-title":"Front Oncol"},{"key":"655_CR20","first-page":"vbad003","volume":"3","author":"Z Li","year":"2023","unstructured":"Li Z, Nagai JS, Kuppe C, Kramann R, Costa IG. ScMEGA: single-cell multi-omic enhancer-based gene regulatory network inference. Bioinf Adv. 2023;3:vbad003.","journal-title":"Bioinf Adv"},{"issue":"D1","key":"655_CR21","doi-asserted-by":"publisher","first-page":"D901","DOI":"10.1093\/nar\/gkae1039","volume":"53","author":"L Shi","year":"2025","unstructured":"Shi L, Li S, Zhu R, Lu C, Xu X, Li C, et al. CRISPRepi: a multi-omic atlas for CRISPR-based epigenome editing. Nucleic Acids Res. 2025;53(D1):D901\u201313.","journal-title":"Nucleic Acids Res"},{"key":"655_CR22","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/nature14289","volume":"521","author":"RC Adam","year":"2015","unstructured":"Adam RC, et al. Pioneer factors govern super-enhancer dynamics in stem cell plasticity and lineage choice. Nature. 2015;521:366\u201370.","journal-title":"Nature"},{"key":"655_CR23","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.gpb.2017.02.003","volume":"15","author":"H Chen","year":"2017","unstructured":"Chen H, Du G, Song X, Li L. Non-coding transcripts from enhancers: new insights into enhancer activity and gene expression regulation. Genomics Proteom Bioinf. 2017;15:201\u20137.","journal-title":"Genomics Proteom Bioinf"},{"key":"655_CR24","doi-asserted-by":"publisher","first-page":"e1002304","DOI":"10.1371\/journal.pcbi.1002304","volume":"7","author":"J G\u00f6ke","year":"2011","unstructured":"G\u00f6ke J, et al. Combinatorial binding in human and mouse embryonic stem cells identifies conserved enhancers active in early embryonic development. PLoS Comput Biol. 2011;7:e1002304.","journal-title":"PLoS Comput Biol"},{"key":"655_CR25","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1126\/science.1232542","volume":"339","author":"CD Arnold","year":"2013","unstructured":"Arnold CD, et al. Genome-wide quantitative enhancer activity maps identified by STARR-seq. Science. 2013;339:1074\u20137.","journal-title":"Science"},{"key":"655_CR26","doi-asserted-by":"publisher","first-page":"eabf5733","DOI":"10.1126\/sciadv.abf5733","volume":"7","author":"R Lopes","year":"2021","unstructured":"Lopes R, et al. Systematic dissection of transcriptional regulatory networks by genome-scale and single-cell CRISPR screens. Sci Adv. 2021;7:eabf5733.","journal-title":"Sci Adv"},{"key":"655_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-021-01464-x","volume":"20","author":"E Dai","year":"2021","unstructured":"Dai E, et al. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy. Mol Cancer. 2021;20:1\u201327.","journal-title":"Mol Cancer"},{"key":"655_CR28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/genes10010043","volume":"10","author":"NV Carullo","year":"2019","unstructured":"Carullo NV, Day JJ. Genomic enhancers in brain health and disease. Genes. 2019;10:43.","journal-title":"Genes"},{"key":"655_CR29","doi-asserted-by":"publisher","first-page":"732033","DOI":"10.3389\/fgene.2021.732033","volume":"12","author":"M Behrends","year":"2021","unstructured":"Behrends M, Engmann O. Loop interrupted: dysfunctional chromatin relations in neurological diseases. Front Genet. 2021;12:732033.","journal-title":"Front Genet"},{"key":"655_CR30","doi-asserted-by":"crossref","unstructured":"Flanagan JM. Epigenome-wide association studies (EWAS): past, present, and future. Cancer Epigenetics: Risk Assessment, Diagnosis, Treatment, and Prognosis. 2014:51\u201363.","DOI":"10.1007\/978-1-4939-1804-1_3"},{"key":"655_CR31","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/ph17010041","volume":"17","author":"S Hasselbeck","year":"2023","unstructured":"Hasselbeck S, Cheng X. Molecular marvels: small molecules paving the way for enhanced gene therapy. Pharmaceuticals. 2023;17:41.","journal-title":"Pharmaceuticals"},{"key":"655_CR32","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3345\/cep.2021.01438","volume":"65","author":"D Lee","year":"2021","unstructured":"Lee D, Kim S. Knowledge-guided artificial intelligence technologies for decoding complex multiomics interactions in cells. Clin Experimental Pediatr. 2021;65:239.","journal-title":"Clin Experimental Pediatr"},{"key":"655_CR33","unstructured":"Senan S, Reddy AJ, Nussbaum Z, Wenteler A, Bejan M, Love MI, et al. Dna-diffusion: leveraging generative models for controlling chromatin accessibility and gene expression via synthetic regulatory elements. InICLR 2024 Workshop on Machine Learning for Genomics Explorations 2024 Feb 1."},{"key":"655_CR34","doi-asserted-by":"crossref","unstructured":"Riethoven J-JM. Regulatory regions in DNA: promoters, enhancers, silencers, and insulators. Comput Biology Transcription Factor Binding. 2010;33\u201342.","DOI":"10.1007\/978-1-60761-854-6_3"},{"key":"655_CR35","doi-asserted-by":"publisher","first-page":"10843","DOI":"10.3390\/ijms241310843","volume":"24","author":"X Wang","year":"2023","unstructured":"Wang X, Liu D, Luo J, Kong D, Zhang Y. Exploring the role of enhancer-mediated transcriptional regulation in precision biology. Int J Mol Sci. 2023;24:10843.","journal-title":"Int J Mol Sci"},{"key":"655_CR36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-022-01518-8","volume":"21","author":"S-W Wang","year":"2022","unstructured":"Wang S-W, et al. Current applications and future perspective of CRISPR\/Cas9 gene editing in cancer. Mol Cancer. 2022;21:57.","journal-title":"Mol Cancer"},{"key":"655_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1101\/gad.179804.111","volume":"26","author":"E De Wit","year":"2012","unstructured":"De Wit E, De Laat W. A decade of 3\u00a0C technologies: insights into nuclear organization. Genes Development. 2012;26:11\u201324.","journal-title":"Genes Development"},{"key":"655_CR38","unstructured":"Cooper G. The Endoplasmic Reticulum in The Cell: A Molecular Approach https:\/\/www.ncbi.nlm.nih.gov\/books. NBK9889 (2000)."},{"key":"655_CR39","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nature06008","volume":"448","author":"TS Mikkelsen","year":"2007","unstructured":"Mikkelsen TS, et al. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature. 2007;448:553\u201360.","journal-title":"Nature"},{"key":"655_CR40","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/j.cell.2014.11.021","volume":"159","author":"SS Rao","year":"2014","unstructured":"Rao SS, et al. A 3D map of the human genome at Kilobase resolution reveals principles of chromatin looping. Cell. 2014;159:1665\u201380.","journal-title":"Cell"},{"key":"655_CR41","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/nmeth.1246","volume":"5","author":"A Valouev","year":"2008","unstructured":"Valouev A, et al. Genome-wide analysis of transcription factor binding sites based on ChIP-Seq data. Nat Methods. 2008;5:829\u201334.","journal-title":"Nat Methods"},{"key":"655_CR42","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.tcb.2014.07.004","volume":"24","author":"J van Arensbergen","year":"2014","unstructured":"van Arensbergen J, van Steensel B, Bussemaker HJ. In search of the determinants of enhancer\u2013promoter interaction specificity. Trends Cell Biol. 2014;24:695\u2013702.","journal-title":"Trends Cell Biol"},{"key":"655_CR43","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.3390\/cells13231963","volume":"13","author":"V Artemyev","year":"2024","unstructured":"Artemyev V, et al. Synthetic promoters in gene therapy: design Approaches, features and applications. Cells. 2024;13:1963.","journal-title":"Cells"},{"key":"655_CR44","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/nrd.2018.110","volume":"17","author":"BE Deverman","year":"2018","unstructured":"Deverman BE, Ravina BM, Bankiewicz KS, Paul SM, Sah DW. Gene therapy for neurological disorders: progress and prospects. Nat Rev Drug Discovery. 2018;17:641\u201359.","journal-title":"Nat Rev Drug Discovery"},{"key":"655_CR45","doi-asserted-by":"publisher","first-page":"606285","DOI":"10.3389\/fgene.2020.606285","volume":"11","author":"M Fagny","year":"2021","unstructured":"Fagny M, et al. Identification of key tissue-specific, biological processes by integrating enhancer information in maize gene regulatory networks. Front Genet. 2021;11:606285.","journal-title":"Front Genet"},{"key":"655_CR46","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nrg2957","volume":"12","author":"C-T Ong","year":"2011","unstructured":"Ong C-T, Corces VG. Enhancer function: new insights into the regulation of tissue-specific gene expression. Nat Rev Genet. 2011;12:283\u201393.","journal-title":"Nat Rev Genet"},{"key":"655_CR47","doi-asserted-by":"publisher","first-page":"2205758","DOI":"10.1080\/19491034.2023.2205758","volume":"14","author":"R Mann","year":"2023","unstructured":"Mann R, Notani D. Transcription factor condensates and signaling driven transcription. Nucleus. 2023;14:2205758.","journal-title":"Nucleus"},{"key":"655_CR48","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s41576-020-0270-8","volume":"21","author":"Z Dai","year":"2020","unstructured":"Dai Z, Ramesh V, Locasale JW. The evolving metabolic landscape of chromatin biology and epigenetics. Nat Rev Genet. 2020;21:737\u201353.","journal-title":"Nat Rev Genet"},{"key":"655_CR49","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13059-021-02322-1","volume":"22","author":"A Panigrahi","year":"2021","unstructured":"Panigrahi A, O\u2019Malley BW. Mechanisms of enhancer action: the known and the unknown. Genome Biol. 2021;22:108.","journal-title":"Genome Biol"},{"key":"655_CR50","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41576-020-00300-0","volume":"22","author":"B Carter","year":"2021","unstructured":"Carter B, Zhao K. The epigenetic basis of cellular heterogeneity. Nat Rev Genet. 2021;22:235\u201350.","journal-title":"Nat Rev Genet"},{"key":"655_CR51","doi-asserted-by":"publisher","first-page":"e02224","DOI":"10.7554\/eLife.02224","volume":"3","author":"Q Zhu","year":"2014","unstructured":"Zhu Q, et al. The transcription factor Pou3f1 promotes neural fate commitment via activation of neural lineage genes and Inhibition of external signaling pathways. Elife. 2014;3:e02224.","journal-title":"Elife"},{"key":"655_CR52","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/cncr.32672","volume":"126","author":"S Zhang","year":"2020","unstructured":"Zhang S, O\u2019Regan R, Xu W. The emerging role of mediator complex subunit 12 in tumorigenesis and response to chemotherapeutics. Cancer. 2020;126:939\u201348.","journal-title":"Cancer"},{"key":"655_CR53","doi-asserted-by":"publisher","first-page":"6285","DOI":"10.1021\/cr3000829","volume":"112","author":"D Lemoine","year":"2012","unstructured":"Lemoine D, et al. Ligand-gated ion channels: new insights into neurological disorders and ligand recognition. Chem Rev. 2012;112:6285\u2013318.","journal-title":"Chem Rev"},{"key":"655_CR54","doi-asserted-by":"publisher","first-page":"aac7341","DOI":"10.1126\/science.aac7341","volume":"352","author":"AA Nielsen","year":"2016","unstructured":"Nielsen AA, et al. Genetic circuit design automation. Science. 2016;352:aac7341.","journal-title":"Science"},{"key":"655_CR55","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.tibtech.2023.09.010","volume":"42","author":"B Bhatt","year":"2024","unstructured":"Bhatt B, Garc\u00eda-D\u00edaz P, Foight GW. Synthetic transcription factor engineering for cell and gene therapy. Trends Biotechnol. 2024;42:449\u201363.","journal-title":"Trends Biotechnol"},{"key":"655_CR56","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41578-020-00265-w","volume":"6","author":"T-C Tang","year":"2021","unstructured":"Tang T-C, et al. Materials design by synthetic biology. Nat Reviews Mater. 2021;6:332\u201350.","journal-title":"Nat Reviews Mater"},{"key":"655_CR57","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.celrep.2017.10.001","volume":"21","author":"AR Sonawane","year":"2017","unstructured":"Sonawane AR, et al. Understanding tissue-specific gene regulation. Cell Rep. 2017;21:1077\u201388.","journal-title":"Cell Rep"},{"key":"655_CR58","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.cell.2011.06.024","volume":"146","author":"R Amit","year":"2011","unstructured":"Amit R, Garcia HG, Phillips R, Fraser SE. Building enhancers from the ground up: a synthetic biology approach. Cell. 2011;146:105\u201318.","journal-title":"Cell"},{"key":"655_CR59","doi-asserted-by":"publisher","first-page":"e14780","DOI":"10.7717\/peerj.14780","volume":"11","author":"Z Yang","year":"2023","unstructured":"Yang Z, Liu Y, Cheng Q, Chen T. Targeting super enhancers for liver disease: a review. PeerJ. 2023;11:e14780.","journal-title":"PeerJ"},{"key":"655_CR60","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41586-023-06936-2","volume":"626","author":"II Taskiran","year":"2024","unstructured":"Taskiran II, et al. Cell-type-directed design of synthetic enhancers. Nature. 2024;626:212\u201320.","journal-title":"Nature"},{"key":"655_CR61","doi-asserted-by":"publisher","first-page":"15491","DOI":"10.1038\/s41598-020-72496-4","volume":"10","author":"AK Golov","year":"2020","unstructured":"Golov AK, et al. A modified protocol of Capture-C allows affordable and flexible high-resolution promoter interactome analysis. Sci Rep. 2020;10:15491.","journal-title":"Sci Rep"},{"key":"655_CR62","doi-asserted-by":"publisher","first-page":"769390","DOI":"10.3389\/fonc.2021.769390","volume":"11","author":"P Huang","year":"2021","unstructured":"Huang P, et al. Integrative analysis of epigenome and transcriptome data reveals aberrantly methylated promoters and enhancers in hepatocellular carcinoma. Front Oncol. 2021;11:769390.","journal-title":"Front Oncol"},{"key":"655_CR63","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/nbt928","volume":"22","author":"P Karande","year":"2004","unstructured":"Karande P, Jain A, Mitragotri S. Discovery of transdermal penetration enhancers by high-throughput screening. Nat Biotechnol. 2004;22:192\u20137.","journal-title":"Nat Biotechnol"},{"key":"655_CR64","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13059-023-02955-4","volume":"24","author":"GD Smith","year":"2023","unstructured":"Smith GD, Ching WH, Cornejo-P\u00e1ramo P, Wong ES. Decoding enhancer complexity with machine learning and high-throughput discovery. Genome Biol. 2023;24:116.","journal-title":"Genome Biol"},{"key":"655_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13148-021-01126-1","volume":"13","author":"TH Beacon","year":"2021","unstructured":"Beacon TH, et al. The dynamic broad epigenetic (H3K4me3, H3K27ac) domain as a mark of essential genes. Clin Epigenetics. 2021;13:1\u201317.","journal-title":"Clin Epigenetics"},{"key":"655_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12864-017-4353-7","volume":"18","author":"A Sharifi-Zarchi","year":"2017","unstructured":"Sharifi-Zarchi A, et al. DNA methylation regulates discrimination of enhancers from promoters through a H3K4me1-H3K4me3 Seesaw mechanism. BMC Genomics. 2017;18:1\u201321.","journal-title":"BMC Genomics"},{"key":"655_CR67","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ygeno.2015.06.005","volume":"106","author":"F Inoue","year":"2015","unstructured":"Inoue F, Ahituv N. Decoding enhancers using massively parallel reporter assays. Genomics. 2015;106:159\u201364.","journal-title":"Genomics"},{"key":"655_CR68","doi-asserted-by":"publisher","first-page":"102199","DOI":"10.1016\/j.gde.2024.102199","volume":"86","author":"X Wang","year":"2024","unstructured":"Wang X, Yue F. Hijacked enhancer\u2013promoter and silencer\u2013promoter loops in cancer. Current Opin Genetics Development. 2024;86:102199.","journal-title":"Current Opin Genetics Development"},{"key":"655_CR69","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1134\/S0006297916070063","volume":"81","author":"A Lukashev","year":"2016","unstructured":"Lukashev A, Zamyatnin A. Viral vectors for gene therapy: current state and clinical perspectives. Biochem (Moscow). 2016;81:700\u20138.","journal-title":"Biochem (Moscow)"},{"key":"655_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-020-02194-x","volume":"21","author":"D Lee","year":"2020","unstructured":"Lee D, et al. STARRPeaker: uniform processing and accurate identification of STARR-seq active regions. Genome Biol. 2020;21:1\u201324.","journal-title":"Genome Biol"},{"issue":"8","key":"655_CR71","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.tibtech.2024.02.007","volume":"42","author":"T Clark","year":"2024","unstructured":"Clark T, Waller MA, Loo L, Moreno CL, Denes CE, Neely GG. CRISPR activation screens: navigating technologies and applications. Trends Biotechnol. 2024;42(8):1017\u201334.","journal-title":"Trends Biotechnol"},{"key":"655_CR72","first-page":"980","volume":"17","author":"A Mora","year":"2016","unstructured":"Mora A, Sandve GK, Gabrielsen OS, Eskeland R. In the loop: promoter\u2013enhancer interactions and bioinformatics. Brief Bioinform. 2016;17:980\u201395.","journal-title":"Brief Bioinform"},{"key":"655_CR73","doi-asserted-by":"crossref","unstructured":"Yuan S, Ni P, Su Z. Simultaneous Prediction of Functional States and Types of cis-regulatory Modules Reveals Their Prevalent Dual Uses as Enhancers and Silencers. bioRxiv 2024\u201305. 2024.","DOI":"10.1101\/2024.05.07.592879"},{"key":"655_CR74","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12964-023-01206-0","volume":"21","author":"Q Li","year":"2023","unstructured":"Li Q, et al. Enhancer rnas: mechanisms in transcriptional regulation and functions in diseases. Cell Communication Signal. 2023;21:191.","journal-title":"Cell Communication Signal"},{"key":"655_CR75","doi-asserted-by":"publisher","first-page":"e166","DOI":"10.1038\/emm.2015.33","volume":"47","author":"S Kim","year":"2015","unstructured":"Kim S, Yu N-K, Kaang B-K. CTCF as a multifunctional protein in genome regulation and gene expression. Experimental Molecular Medicine. 2015;47:e166\u2013166.","journal-title":"Experimental Molecular Medicine"},{"key":"655_CR76","doi-asserted-by":"publisher","first-page":"462","DOI":"10.3389\/fimmu.2015.00462","volume":"6","author":"ML Nguyen","year":"2015","unstructured":"Nguyen ML, Jones SA, Prier JE, Russ BE. Transcriptional enhancers in the regulation of T cell differentiation. Front Immunol. 2015;6:462.","journal-title":"Front Immunol"},{"key":"655_CR77","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41576-018-0001-6","volume":"19","author":"A Vihervaara","year":"2018","unstructured":"Vihervaara A, Duarte FM, Lis JT. Molecular mechanisms driving transcriptional stress responses. Nat Rev Genet. 2018;19:385\u201397.","journal-title":"Nat Rev Genet"},{"key":"655_CR78","doi-asserted-by":"publisher","first-page":"dev182667","DOI":"10.1242\/dev.182667","volume":"148","author":"E Akinci","year":"2021","unstructured":"Akinci E, Hamilton MC, Khowpinitchai B. Sherwood, R. I. Using CRISPR to understand and manipulate gene regulation. Development. 2021;148:dev182667.","journal-title":"Development"},{"key":"655_CR79","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","volume":"157","author":"PD Hsu","year":"2014","unstructured":"Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell. 2014;157:1262\u201378.","journal-title":"Cell"},{"key":"655_CR80","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.3389\/fonc.2020.01387","volume":"10","author":"F Uddin","year":"2020","unstructured":"Uddin F, Rudin CM, Sen T. CRISPR gene therapy: applications, limitations, and implications for the future. Front Oncol. 2020;10:1387.","journal-title":"Front Oncol"},{"key":"655_CR81","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1038\/s41591-022-01906-z","volume":"28","author":"B Fu","year":"2022","unstructured":"Fu B, et al. CRISPR\u2013Cas9-mediated gene editing of the BCL11A enhancer for pediatric \u03b20\/\u03b20 transfusion-dependent \u03b2-thalassemia. Nat Med. 2022;28:1573\u201380.","journal-title":"Nat Med"},{"key":"655_CR82","doi-asserted-by":"publisher","first-page":"BSR20160183","DOI":"10.1042\/BSR20160183","volume":"37","author":"Z Hu","year":"2017","unstructured":"Hu Z, Tee W-W. Enhancers and chromatin structures: regulatory hubs in gene expression and diseases. Biosci Rep. 2017;37:BSR20160183.","journal-title":"Biosci Rep"},{"key":"655_CR83","doi-asserted-by":"crossref","unstructured":"Shao M et al. Multi-omics mediated wide association studies: novel approaches for Understanding diseases. Genomics Proteomics Bioinformatics qzae077. 2024.","DOI":"10.1093\/gpbjnl\/qzae077"},{"key":"655_CR84","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/s41576-019-0209-0","volume":"21","author":"M Gasperini","year":"2020","unstructured":"Gasperini M, Tome JM, Shendure J. Towards a comprehensive catalogue of validated and target-linked human enhancers. Nat Rev Genet. 2020;21:292\u2013310.","journal-title":"Nat Rev Genet"},{"key":"655_CR85","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","volume":"21","author":"C Li","year":"2020","unstructured":"Li C, Samulski RJ. Engineering adeno-associated virus vectors for gene therapy. Nat Rev Genet. 2020;21:255\u201372.","journal-title":"Nat Rev Genet"},{"key":"655_CR86","doi-asserted-by":"publisher","first-page":"5714","DOI":"10.1038\/s41467-023-41033-y","volume":"14","author":"J Li","year":"2023","unstructured":"Li J, et al. Divergent single cell transcriptome and epigenome alterations in ALS and FTD patients with C9orf72 mutation. Nat Commun. 2023;14:5714.","journal-title":"Nat Commun"},{"key":"655_CR87","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.omtm.2021.08.002","volume":"23","author":"LF Barnes","year":"2021","unstructured":"Barnes LF, Draper BE, Chen Y-T, Powers TW, Jarrold MF. Quantitative analysis of genome packaging in Recombinant AAV vectors by charge detection mass spectrometry. Molecular Therapy Methods Clinical Development. 2021;23:87\u201397.","journal-title":"Molecular Therapy Methods Clinical Development"},{"key":"655_CR88","volume-title":"The role of Gfi1 family oncogenes in Medulloblastoma","author":"C Lee","year":"2016","unstructured":"Lee C. The role of Gfi1 family oncogenes in Medulloblastoma. San Diego: University of California; 2016."},{"key":"655_CR89","doi-asserted-by":"publisher","first-page":"108123","DOI":"10.1016\/j.pharmthera.2022.108123","volume":"234","author":"H Wang","year":"2022","unstructured":"Wang H, et al. RNA-based diagnostic markers discovery and therapeutic targets development in cancer. Pharmacology Therapeutics. 2022;234:108123.","journal-title":"Pharmacology Therapeutics"},{"key":"655_CR90","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1021\/acschemneuro.1c00701","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, et al. Epigenetic modifications and neurodegenerative disorders: A biochemical perspective. ACS Chem Neurosci. 2022;13:177\u201384.","journal-title":"ACS Chem Neurosci"},{"key":"655_CR91","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/nan.12757","volume":"47","author":"M Murthy","year":"2021","unstructured":"Murthy M, Cheng YY, Holton JL, Bettencourt C. Neurodegenerative movement disorders: an epigenetics perspective and promise for the future. Neuropathol Appl Neurobiol. 2021;47:897\u2013909.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"655_CR92","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1038\/s41467-019-10101-7","volume":"10","author":"P Li","year":"2019","unstructured":"Li P, et al. Epigenetic dysregulation of enhancers in neurons is associated with alzheimer\u2019s disease pathology and cognitive symptoms. Nat Commun. 2019;10:2246.","journal-title":"Nat Commun"},{"key":"655_CR93","doi-asserted-by":"publisher","first-page":"8547","DOI":"10.1523\/JNEUROSCI.1006-23.2023","volume":"43","author":"Y Tao","year":"2023","unstructured":"Tao Y, et al. Spinal-specific super enhancer in neuropathic pain. J Neurosci. 2023;43:8547\u201361.","journal-title":"J Neurosci"},{"key":"655_CR94","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1038\/s41467-019-10101-7","volume":"10","author":"P Li","year":"2019","unstructured":"Li P, et al. Epigenetic dysregulation of enhancers in neurons is associated with alzheimer\u2019s disease pathology and cognitive symptoms. Nat Commun. 2019;10:2246.","journal-title":"Nat Commun"},{"key":"655_CR95","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41380-018-0036-2","volume":"24","author":"T Toda","year":"2019","unstructured":"Toda T, Parylak SL, Linker SB, Gage FH. The role of adult hippocampal neurogenesis in brain health and disease. Mol Psychiatry. 2019;24:67\u201387.","journal-title":"Mol Psychiatry"},{"key":"655_CR96","unstructured":"Hunker AC et al. Enhancer AAV toolbox for accessing and perturbing striatal cell types and circuits. bioRxiv. 2024."},{"key":"655_CR97","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/joim.12759","volume":"284","author":"R Loera-Valencia","year":"2018","unstructured":"Loera-Valencia R, et al. Targeting alzheimer\u2019s disease with gene and cell therapies. J Intern Med. 2018;284:2\u201336.","journal-title":"J Intern Med"},{"key":"655_CR98","doi-asserted-by":"publisher","first-page":"7333","DOI":"10.3390\/ijms25137333","volume":"25","author":"M Taghdiri","year":"2024","unstructured":"Taghdiri M, Mussolino C. Viral and non-viral systems to deliver gene therapeutics to clinical targets. Int J Mol Sci. 2024;25:7333.","journal-title":"Int J Mol Sci"},{"key":"655_CR99","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3390\/ph15091077","volume":"15","author":"H Ashraf","year":"2022","unstructured":"Ashraf H, Solla P, Sechi LA. Current advancement of Immunomodulatory drugs as potential pharmacotherapies for autoimmunity based neurological diseases. Pharmaceuticals. 2022;15:1077.","journal-title":"Pharmaceuticals"},{"key":"655_CR100","doi-asserted-by":"publisher","first-page":"eadh5313","DOI":"10.1126\/sciadv.adh5313","volume":"9","author":"I Zlatanova","year":"2023","unstructured":"Zlatanova I, et al. An injury-responsive mmp14b enhancer is required for heart regeneration. Sci Adv. 2023;9:eadh5313.","journal-title":"Sci Adv"},{"key":"655_CR101","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.stem.2022.11.012","volume":"30","author":"R Yan","year":"2023","unstructured":"Yan R, et al. An enhancer-based gene-therapy strategy for Spatiotemporal control of cargoes during tissue repair. Cell Stem Cell. 2023;30:96\u2013111.","journal-title":"Cell Stem Cell"},{"key":"655_CR102","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1002\/jcp.27200","volume":"234","author":"X He","year":"2019","unstructured":"He X, Zeng H, Chen J. Emerging role of SIRT3 in endothelial metabolism, angiogenesis, and cardiovascular disease. J Cell Physiol. 2019;234:2252\u201365.","journal-title":"J Cell Physiol"},{"key":"655_CR103","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41569-021-00597-2","volume":"19","author":"CG Anene-Nzelu","year":"2022","unstructured":"Anene-Nzelu CG, Lee MC, Tan WL, Dashi A, Foo RS. Genomic enhancers in cardiac development and disease. Nat Reviews Cardiol. 2022;19:7\u201325.","journal-title":"Nat Reviews Cardiol"},{"key":"655_CR104","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41569-021-00597-2","volume":"19","author":"CG Anene-Nzelu","year":"2022","unstructured":"Anene-Nzelu CG, Lee MC, Tan WL, Dashi A, Foo RS. Genomic enhancers in cardiac development and disease. Nat Reviews Cardiol. 2022;19:7\u201325.","journal-title":"Nat Reviews Cardiol"},{"key":"655_CR105","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1016\/j.bbamcr.2015.11.026","volume":"1863","author":"S Ounzain","year":"2016","unstructured":"Ounzain S, Pedrazzini T. Super-enhancer Lncs to cardiovascular development and disease. Biochim Et Biophys Acta (BBA)-Molecular Cell Res. 2016;1863:1953\u201360.","journal-title":"Biochim Et Biophys Acta (BBA)-Molecular Cell Res"},{"key":"655_CR106","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1177\/1947601911423031","volume":"2","author":"M Shibuya","year":"2011","unstructured":"Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti-and pro-angiogenic therapies. Genes Cancer. 2011;2:1097\u2013105.","journal-title":"Genes Cancer"},{"key":"655_CR107","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1161\/CIRCRESAHA.114.302331","volume":"114","author":"S Zacchigna","year":"2014","unstructured":"Zacchigna S, Zentilin L, Giacca M. Adeno-associated virus vectors as therapeutic and investigational tools in the cardiovascular system. Circul Res. 2014;114:1827\u201346.","journal-title":"Circul Res"},{"key":"655_CR108","first-page":"232","volume":"2","author":"CA Holladay","year":"2010","unstructured":"Holladay CA, O\u2019Brien T, Pandit A. Non-viral gene therapy for myocardial engineering. Wiley Interdisciplinary Reviews: Nanomed Nanobiotechnol. 2010;2:232\u201348.","journal-title":"Wiley Interdisciplinary Reviews: Nanomed Nanobiotechnol"},{"key":"655_CR109","doi-asserted-by":"publisher","first-page":"760140","DOI":"10.3389\/fcvm.2021.760140","volume":"8","author":"G Cao","year":"2021","unstructured":"Cao G, Xuan X, Zhang R, Hu J, Dong H. Gene therapy for cardiovascular disease: basic research and clinical prospects. Front Cardiovasc Med. 2021;8:760140.","journal-title":"Front Cardiovasc Med"},{"key":"655_CR110","doi-asserted-by":"publisher","first-page":"106480","DOI":"10.1016\/j.phrs.2022.106480","volume":"185","author":"M Dong","year":"2022","unstructured":"Dong M, et al. CRISPR\/CAS9: a promising approach for the research and treatment of cardiovascular diseases. Pharmacol Res. 2022;185:106480.","journal-title":"Pharmacol Res"},{"key":"655_CR111","doi-asserted-by":"publisher","first-page":"760140","DOI":"10.3389\/fcvm.2021.760140","volume":"8","author":"G Cao","year":"2021","unstructured":"Cao G, Xuan X, Zhang R, Hu J, Dong H. Gene therapy for cardiovascular disease: basic research and clinical prospects. Front Cardiovasc Med. 2021;8:760140.","journal-title":"Front Cardiovasc Med"},{"key":"655_CR112","unstructured":"Peat TJ. Cooperative Drug Combinations Target Oncogenes and Tumor Suppressors in Cancer. 2021."},{"key":"655_CR113","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1158\/0008-5472.CAN-16-2301","volume":"77","author":"C Koschmann","year":"2017","unstructured":"Koschmann C, et al. Mutated chromatin regulatory factors as tumor drivers in cancer. Cancer Res. 2017;77:227\u201333.","journal-title":"Cancer Res"},{"key":"655_CR114","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41698-020-0108-z","volume":"4","author":"F Tang","year":"2020","unstructured":"Tang F, Yang Z, Tan Y, Li Y. Super-enhancer function and its application in cancer targeted therapy. NPJ Precision Oncol. 2020;4:2.","journal-title":"NPJ Precision Oncol"},{"key":"655_CR115","doi-asserted-by":"crossref","unstructured":"Dan H, Zhang S, Zhou Y, Guan Q. DNA methyltransferase inhibitors: catalysts for antitumour immune responses. OncoTargets Therapy. 2019;10903\u201316.","DOI":"10.2147\/OTT.S217767"},{"key":"655_CR116","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrc1779","volume":"6","author":"S Minucci","year":"2006","unstructured":"Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006;6:38\u201351.","journal-title":"Nat Rev Cancer"},{"key":"655_CR117","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1089\/hum.2015.067","volume":"26","author":"S Yao","year":"2015","unstructured":"Yao S, He Z, Chen C. CRISPR\/Cas9-mediated genome editing of epigenetic factors for cancer therapy. Hum Gene Ther. 2015;26:463\u201371.","journal-title":"Hum Gene Ther"},{"key":"655_CR118","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nrc.2016.62","volume":"16","author":"I Sur","year":"2016","unstructured":"Sur I, Taipale J. The role of enhancers in cancer. Nat Rev Cancer. 2016;16:483\u201393.","journal-title":"Nat Rev Cancer"},{"key":"655_CR119","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1089\/1545457041526290","volume":"14","author":"S Coma","year":"2004","unstructured":"Coma S, et al. Use of SiRNAs and antisense oligonucleotides against survivin RNA to inhibit steps leading to tumor angiogenesis. Oligonucleotides. 2004;14:100\u201313.","journal-title":"Oligonucleotides"},{"key":"655_CR120","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41594-020-0446-0","volume":"27","author":"V Sartorelli","year":"2020","unstructured":"Sartorelli V, Lauberth SM. Enhancer RNAs are an important regulatory layer of the epigenome. Nature Structural Molecular Biology. 2020;27:521\u20138.","journal-title":"Nature Structural Molecular Biology"},{"key":"655_CR121","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41467-020-14362-5","volume":"11","author":"K Li","year":"2020","unstructured":"Li K, et al. Interrogation of enhancer function by enhancer-targeting CRISPR epigenetic editing. Nat Commun. 2020;11:485.","journal-title":"Nat Commun"},{"key":"655_CR122","doi-asserted-by":"crossref","unstructured":"Nott A et al. Cell type-specific enhancer-promoter connectivity maps in the human brain and disease risk association. BioRxiv. 2019;778183.","DOI":"10.1002\/alz.047113"},{"key":"655_CR123","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrm.2016.79","volume":"17","author":"R Lopes","year":"2016","unstructured":"Lopes R, Korkmaz G, Agami R. Applying CRISPR\u2013Cas9 tools to identify and characterize transcriptional enhancers. Nat Rev Mol Cell Biol. 2016;17:597\u2013604.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"655_CR124","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41467-017-00479-7","volume":"8","author":"S Mettananda","year":"2017","unstructured":"Mettananda S, et al. Editing an \u03b1-globin enhancer in primary human hematopoietic stem cells as a treatment for \u03b2-thalassemia. Nat Commun. 2017;8:424.","journal-title":"Nat Commun"},{"key":"655_CR125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-19505-2","volume":"11","author":"K Bulaklak","year":"2020","unstructured":"Bulaklak K, Gersbach CA. The once and future gene therapy. Nat Commun. 2020;11:1\u20134.","journal-title":"Nat Commun"},{"key":"655_CR126","doi-asserted-by":"publisher","first-page":"eaaz3090","DOI":"10.1126\/science.aaz3090","volume":"369","author":"W Wang","year":"2020","unstructured":"Wang W, et al. Changes in regeneration-responsive enhancers shape regenerative capacities in vertebrates. Science. 2020;369:eaaz3090.","journal-title":"Science"},{"key":"655_CR127","doi-asserted-by":"publisher","first-page":"153382","DOI":"10.1016\/j.prp.2021.153382","volume":"220","author":"RG Marangoni","year":"2021","unstructured":"Marangoni RG, et al. Pathological pulmonary vascular remodeling is induced by type V collagen in a model of scleroderma. Pathology-Research Pract. 2021;220:153382.","journal-title":"Pathology-Research Pract"},{"key":"655_CR128","doi-asserted-by":"publisher","first-page":"R42","DOI":"10.1093\/hmg\/ddv451","volume":"25","author":"JC Van Der Loo","year":"2016","unstructured":"Van Der Loo JC, Wright JF. Progress and challenges in viral vector manufacturing. Hum Mol Genet. 2016;25:R42\u201352.","journal-title":"Hum Mol Genet"},{"key":"655_CR129","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/BF00210632","volume":"74","author":"W Walther","year":"1996","unstructured":"Walther W, Stein U. Cell type specific and inducible promoters for vectors in gene therapy as an approach for cell targeting. J Mol Med. 1996;74:379\u201392.","journal-title":"J Mol Med"},{"key":"655_CR130","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41420-025-02366-3","volume":"11","author":"J Yang","year":"2025","unstructured":"Yang J, et al. Enhancer reprogramming: critical roles in cancer and promising therapeutic strategies. Cell Death Discovery. 2025;11:84.","journal-title":"Cell Death Discovery"},{"key":"655_CR131","doi-asserted-by":"publisher","first-page":"334","DOI":"10.7555\/JBR.37.20230206","volume":"38","author":"S Chen","year":"2024","unstructured":"Chen S, et al. p53 exerts anticancer effects by regulating enhancer formation and activity. J Biomedical Res. 2024;38:334.","journal-title":"J Biomedical Res"},{"key":"655_CR132","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41586-023-06936-2","volume":"626","author":"II Taskiran","year":"2024","unstructured":"Taskiran II, et al. Cell-type-directed design of synthetic enhancers. Nature. 2024;626:212\u201320.","journal-title":"Nature"},{"key":"655_CR133","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nrc.2016.62","volume":"16","author":"I Sur","year":"2016","unstructured":"Sur I, Taipale J. The role of enhancers in cancer. Nat Rev Cancer. 2016;16:483\u201393.","journal-title":"Nat Rev Cancer"},{"key":"655_CR134","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s10038-017-0377-8","volume":"63","author":"S Nakade","year":"2018","unstructured":"Nakade S, Yamamoto T, Sakuma T. Cancer induction and suppression with transcriptional control and epigenome editing technologies. J Hum Genet. 2018;63:187\u201394.","journal-title":"J Hum Genet"},{"key":"655_CR135","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1089\/hum.2015.067","volume":"26","author":"S Yao","year":"2015","unstructured":"Yao S, He Z, Chen C. CRISPR\/Cas9-mediated genome editing of epigenetic factors for cancer therapy. Hum Gene Ther. 2015;26:463\u201371.","journal-title":"Hum Gene Ther"}],"container-title":["Hereditas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41065-026-00655-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-026-00655-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-026-00655-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:34:40Z","timestamp":1781642080000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41065-026-00655-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,21]]},"references-count":135,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["655"],"URL":"https:\/\/doi.org\/10.1186\/s41065-026-00655-0","relation":{},"ISSN":["1601-5223"],"issn-type":[{"value":"1601-5223","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,21]]},"assertion":[{"value":"4 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}